Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients

Table 1 Clinical characteristics of study subjects

	n	Sex F/M	Age at onset	Age at biopsy	ALSFRS	Rate of progression	FVC (%)	BMI	Onset S/B
Controls	91	0.88	–	60.3 (47–83)	–	–	–	NA	–
sALS	171	0.67	58.3 (26–79)	59.7 (27–80)	34.2 (8–47)	1.0 (0.06–3.4)	76.1 (6–138)	26.4 (16.2–39.7)	1.98
PLS	34	0.79	51.7* (32–74)	59.2 (41–81)	33.2 (14–44)	0.2* (0.07–0.37)	89.6* (31–143)	26.9 (19–34.6)	2.67
C9Orf72	13	1.50	56.3 (40–70)	58.3 (38–72)	34.9 (30–41)	0.9 (0.24–2.0)	79.3 (38–115)	27.8 (20.5–50.4)	3.00

Values indicate averages and values in brackets indicate ranges. Sex F/M, is the female to male ratio; ALSFRS, is the ALS functional rating scale at time of skin biopsy; Rate of progression is the % of ALSFRS decline per month; FVC is the forced vital capacity at time of skin biopsy expressed as % of normal; BMI is the body mass index at time of skin biopsy; Onset S/B is the ratio of site of disease onset, spinal (S) or bulbar (B). NA not available
*p < 0.005 PLS vs. ALS, based on Mann-Whitney U test

ISSN: 1750-1326